Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.84Last Year’s EPS
0.55Same Quarter Last Year
Strong Buy
Based on 18 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -6.75%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
BioMarin reported strong financial performance with notable revenue growth and profitability expansion, supported by successful pipeline progress. However, potential challenges include analyzing exposure to future pharmaceutical tariffs and managing VOXZOGO's revenue dynamics amid global order patterns. The overall sentiment leans towards optimism with strategic growth initiatives and robust financial results.Company Guidance
In the BioMarin Pharmaceuticals First Quarter 2025 Conference Call, the company reported a strong financial performance with a 15% increase in revenue, reaching $745 million, and a 59% year-over-year rise in non-GAAP earnings per share, which stood at $1.13. The growth was fueled by VOXZOGO, which saw a 40% increase in global revenue to $214 million, and PALYNZIQ, which grew by 22%. The non-GAAP operating margin expanded to 35.7%, up by 11.9 percentage points from the previous year. The company reiterated its full-year non-GAAP operating margin guidance of 32% to 33%. BioMarin projects full-year 2025 VOXZOGO revenues between $900 million and $950 million, reflecting a 26% increase at the midpoint. The company also highlighted its strategic transformation, ongoing innovation, and robust global presence as key factors positioning it well amidst market uncertainties, with two-thirds of its revenue originating outside the United States.Strong Revenue Growth
BioMarin reported a 15% increase in total revenues for Q1 2025, reaching $745 million compared to the same period last year. VOXZOGO's global revenue also increased by 40% year-over-year.
Profitability Expansion
Non-GAAP earnings per share reached $1.13, representing a 59% year-over-year increase. Non-GAAP operating margin expanded by 11.9 percentage points year-over-year to 35.7%.
Pipeline Progress
Completed enrollment in a pivotal Phase 3 study with VOXZOGO in children with hypochondroplasia, aiming for a launch in 2027. Progress in BMN 351 for Duchenne Muscular Dystrophy and BMN 333, with early clinical results expected later this year.
Enzyme Therapies Growth
Revenue from the Enzyme Therapies business unit grew 8% year-over-year, with PALYNZIQ increasing by 22% compared to Q1 2024.
Geographical Revenue Diversification
Approximately two-thirds of BioMarin’s total revenues originate from outside the United States, providing insulation from US-specific economic conditions.
BMRN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BMRN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $62.71 | $62.03 | -1.08% |
Feb 19, 2025 | $65.61 | $68.73 | +4.76% |
Oct 29, 2024 | $69.91 | $66.68 | -4.62% |
Aug 05, 2024 | $80.47 | $86.87 | +7.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioMarin Pharmaceutical (BMRN) report earnings?
BioMarin Pharmaceutical (BMRN) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is BioMarin Pharmaceutical (BMRN) earnings time?
BioMarin Pharmaceutical (BMRN) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BMRN EPS forecast?
BMRN EPS forecast for the fiscal quarter 2025 (Q2) is 0.84.
